Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Royalty Pharma Plc
RPRXRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. Address: 110 East 59th Street, New York, NY, United States, 10022
Analytics
Zielpreis von Wall Street
40.02 USDKGV
18.0667Dividendenrendite
3.2 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen RPRX
Dividenden-Analyse RPRX
Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
3 JahreAusschüttungsquote 5-Jahres-Durchschnitt
279 %Verlauf der Dividende RPRX
Bewertung der Aktie RPRX
Finanzen RPRX
Ergebnisse | 2019 | Dynamik |